| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus Infections | 36 | 2024 | 217 | 9.510 |
Why?
|
| Cytomegalovirus | 20 | 2021 | 268 | 4.720 |
Why?
|
| Hearing Loss, Sensorineural | 9 | 2024 | 141 | 1.560 |
Why?
|
| Neonatal Screening | 9 | 2024 | 184 | 1.480 |
Why?
|
| Influenza, Human | 13 | 2013 | 649 | 1.160 |
Why?
|
| Hearing Loss | 4 | 2022 | 131 | 1.130 |
Why?
|
| Pregnancy Complications, Infectious | 7 | 2019 | 444 | 1.090 |
Why?
|
| Antiviral Agents | 12 | 2024 | 744 | 1.030 |
Why?
|
| Ganciclovir | 8 | 2024 | 96 | 0.980 |
Why?
|
| Infant, Newborn | 38 | 2024 | 8104 | 0.970 |
Why?
|
| Influenza A virus | 8 | 2009 | 135 | 0.950 |
Why?
|
| Nervous System Diseases | 3 | 2021 | 369 | 0.920 |
Why?
|
| Influenza B virus | 5 | 2008 | 87 | 0.730 |
Why?
|
| Vestibular Diseases | 1 | 2021 | 67 | 0.670 |
Why?
|
| Adenoviridae | 6 | 2011 | 605 | 0.640 |
Why?
|
| Herpes Simplex | 4 | 2010 | 57 | 0.610 |
Why?
|
| Coinfection | 1 | 2020 | 175 | 0.600 |
Why?
|
| Vision Disorders | 3 | 2019 | 209 | 0.600 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2019 | 237 | 0.580 |
Why?
|
| Zika Virus Infection | 3 | 2022 | 167 | 0.570 |
Why?
|
| Infant | 32 | 2024 | 12339 | 0.550 |
Why?
|
| Child, Preschool | 30 | 2024 | 13878 | 0.550 |
Why?
|
| Humans | 84 | 2024 | 123146 | 0.550 |
Why?
|
| Longitudinal Studies | 9 | 2022 | 1312 | 0.530 |
Why?
|
| Reagent Kits, Diagnostic | 6 | 2008 | 53 | 0.520 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2021 | 485 | 0.520 |
Why?
|
| Child | 38 | 2022 | 24221 | 0.510 |
Why?
|
| Asymptomatic Diseases | 2 | 2019 | 77 | 0.470 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2013 | 178 | 0.460 |
Why?
|
| Zika Virus | 2 | 2022 | 142 | 0.460 |
Why?
|
| Microcephaly | 3 | 2022 | 328 | 0.450 |
Why?
|
| Disease Outbreaks | 5 | 2010 | 320 | 0.440 |
Why?
|
| Antigens, Viral | 6 | 2010 | 436 | 0.440 |
Why?
|
| Epitopes | 1 | 2015 | 430 | 0.430 |
Why?
|
| Antibodies, Viral | 5 | 2020 | 1134 | 0.420 |
Why?
|
| Disease Progression | 3 | 2019 | 2023 | 0.420 |
Why?
|
| Female | 46 | 2024 | 65443 | 0.400 |
Why?
|
| Adolescent | 25 | 2022 | 19093 | 0.380 |
Why?
|
| Dyspnea | 1 | 2022 | 148 | 0.380 |
Why?
|
| Central Nervous System Infections | 2 | 2022 | 21 | 0.380 |
Why?
|
| Virus Diseases | 2 | 2011 | 280 | 0.370 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2011 | 501 | 0.370 |
Why?
|
| Fever of Unknown Origin | 2 | 2020 | 45 | 0.370 |
Why?
|
| Eye Infections, Viral | 2 | 2019 | 28 | 0.370 |
Why?
|
| Adenoviridae Infections | 3 | 2008 | 70 | 0.350 |
Why?
|
| Otitis Media with Effusion | 1 | 2020 | 18 | 0.350 |
Why?
|
| Mucormycosis | 1 | 2020 | 26 | 0.340 |
Why?
|
| Facial Paralysis | 1 | 2020 | 36 | 0.340 |
Why?
|
| Cat-Scratch Disease | 1 | 2020 | 33 | 0.340 |
Why?
|
| Health Surveys | 2 | 2014 | 241 | 0.330 |
Why?
|
| Antifungal Agents | 2 | 2022 | 293 | 0.330 |
Why?
|
| Triazoles | 1 | 2020 | 138 | 0.320 |
Why?
|
| Simplexvirus | 2 | 2010 | 99 | 0.320 |
Why?
|
| Population Surveillance | 1 | 2021 | 383 | 0.310 |
Why?
|
| Chemokines, CXC | 1 | 2008 | 39 | 0.310 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2020 | 226 | 0.300 |
Why?
|
| Herpesvirus 4, Human | 1 | 2011 | 659 | 0.300 |
Why?
|
| Typhus, Endemic Flea-Borne | 1 | 2018 | 20 | 0.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 1196 | 0.290 |
Why?
|
| Hematologic Neoplasms | 1 | 2011 | 287 | 0.290 |
Why?
|
| Thrombocytopenia | 2 | 2018 | 228 | 0.290 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2013 | 204 | 0.290 |
Why?
|
| Visual Cortex | 1 | 2019 | 109 | 0.290 |
Why?
|
| Prenatal Diagnosis | 2 | 2009 | 587 | 0.290 |
Why?
|
| Virus Shedding | 1 | 2017 | 79 | 0.280 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2019 | 215 | 0.280 |
Why?
|
| Male | 34 | 2024 | 60034 | 0.280 |
Why?
|
| Viral Tropism | 1 | 2017 | 42 | 0.280 |
Why?
|
| Asymptomatic Infections | 1 | 2017 | 33 | 0.280 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2013 | 334 | 0.270 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2019 | 105 | 0.270 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 1677 | 0.270 |
Why?
|
| Viral Proteins | 1 | 2008 | 348 | 0.270 |
Why?
|
| Pregnancy | 8 | 2020 | 7142 | 0.260 |
Why?
|
| Opportunistic Infections | 1 | 2006 | 79 | 0.260 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 360 | 0.260 |
Why?
|
| Respiratory System | 3 | 2007 | 95 | 0.260 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 414 | 0.260 |
Why?
|
| Pericarditis | 1 | 2006 | 41 | 0.250 |
Why?
|
| Hearing Tests | 3 | 2020 | 14 | 0.250 |
Why?
|
| Chromatography | 4 | 2008 | 43 | 0.250 |
Why?
|
| DNA, Viral | 4 | 2008 | 477 | 0.250 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 809 | 0.240 |
Why?
|
| Dried Blood Spot Testing | 2 | 2024 | 22 | 0.240 |
Why?
|
| Texas | 9 | 2020 | 3545 | 0.240 |
Why?
|
| Placenta | 1 | 2019 | 493 | 0.240 |
Why?
|
| Antibodies, Neutralizing | 2 | 2017 | 459 | 0.240 |
Why?
|
| Visual Acuity | 1 | 2019 | 806 | 0.230 |
Why?
|
| Hospitals, Pediatric | 3 | 2009 | 780 | 0.230 |
Why?
|
| Bacterial Infections | 2 | 2008 | 305 | 0.230 |
Why?
|
| Anemia | 1 | 2018 | 339 | 0.230 |
Why?
|
| Hypertension | 1 | 2022 | 1284 | 0.220 |
Why?
|
| Time Factors | 9 | 2021 | 6205 | 0.220 |
Why?
|
| Bronchiolitis, Viral | 1 | 2013 | 29 | 0.210 |
Why?
|
| Phaeohyphomycosis | 1 | 2022 | 11 | 0.210 |
Why?
|
| Prevalence | 6 | 2020 | 2405 | 0.210 |
Why?
|
| Epithelial Cells | 1 | 2017 | 900 | 0.210 |
Why?
|
| Cerebral Ventriculitis | 1 | 2022 | 15 | 0.200 |
Why?
|
| Adult | 17 | 2021 | 29029 | 0.200 |
Why?
|
| Sensitivity and Specificity | 8 | 2010 | 2024 | 0.200 |
Why?
|
| Immunoassay | 4 | 2008 | 127 | 0.200 |
Why?
|
| Interferons | 1 | 2013 | 124 | 0.200 |
Why?
|
| Postoperative Complications | 2 | 2011 | 3011 | 0.200 |
Why?
|
| Orthomyxoviridae | 1 | 2002 | 50 | 0.200 |
Why?
|
| Central Nervous System | 2 | 2022 | 253 | 0.190 |
Why?
|
| Neuraminidase | 2 | 2010 | 34 | 0.190 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 2 | 2010 | 118 | 0.180 |
Why?
|
| Brain | 4 | 2019 | 2946 | 0.180 |
Why?
|
| Fetal Diseases | 1 | 2005 | 440 | 0.180 |
Why?
|
| Nervous System Malformations | 1 | 2022 | 127 | 0.180 |
Why?
|
| Bacteremia | 2 | 2006 | 406 | 0.180 |
Why?
|
| Oseltamivir | 1 | 2010 | 16 | 0.170 |
Why?
|
| Virus Cultivation | 5 | 2010 | 76 | 0.170 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 5046 | 0.170 |
Why?
|
| Hearing | 1 | 2020 | 51 | 0.170 |
Why?
|
| Brazil | 1 | 2020 | 121 | 0.170 |
Why?
|
| Mobile Health Units | 1 | 2009 | 24 | 0.170 |
Why?
|
| Intellectual Disability | 1 | 2017 | 1043 | 0.170 |
Why?
|
| Fever | 3 | 2008 | 296 | 0.170 |
Why?
|
| Young Adult | 7 | 2019 | 8864 | 0.170 |
Why?
|
| Students, Medical | 1 | 2014 | 361 | 0.160 |
Why?
|
| Chromatography, Affinity | 1 | 2008 | 70 | 0.160 |
Why?
|
| Haemophilus influenzae type b | 1 | 2008 | 5 | 0.160 |
Why?
|
| Pyomyositis | 1 | 2008 | 3 | 0.160 |
Why?
|
| Prospective Studies | 5 | 2024 | 6027 | 0.160 |
Why?
|
| Acyclovir | 1 | 2008 | 45 | 0.150 |
Why?
|
| Triage | 1 | 2009 | 140 | 0.150 |
Why?
|
| Central Nervous System Diseases | 2 | 2010 | 105 | 0.150 |
Why?
|
| Haemophilus Infections | 1 | 2008 | 92 | 0.150 |
Why?
|
| Intelligence Tests | 1 | 2017 | 57 | 0.150 |
Why?
|
| Breast Feeding | 1 | 2019 | 220 | 0.140 |
Why?
|
| Lung Transplantation | 1 | 2021 | 316 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 2043 | 0.140 |
Why?
|
| Developmental Disabilities | 2 | 2017 | 699 | 0.140 |
Why?
|
| Intelligence | 1 | 2017 | 98 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2009 | 826 | 0.140 |
Why?
|
| Pasteurella Infections | 1 | 2006 | 7 | 0.140 |
Why?
|
| Pasteurella multocida | 1 | 2006 | 8 | 0.140 |
Why?
|
| Age of Onset | 2 | 2019 | 581 | 0.140 |
Why?
|
| Amphotericin B | 2 | 2022 | 90 | 0.140 |
Why?
|
| Educational Status | 1 | 2017 | 270 | 0.130 |
Why?
|
| Molecular Sequence Data | 4 | 2010 | 3870 | 0.130 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1680 | 0.130 |
Why?
|
| Meningitis, Bacterial | 1 | 2006 | 93 | 0.130 |
Why?
|
| Vestibular Aqueduct | 1 | 2005 | 3 | 0.130 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2014 | 22 | 0.120 |
Why?
|
| Chickenpox | 1 | 2014 | 20 | 0.120 |
Why?
|
| BK Virus | 1 | 2005 | 59 | 0.120 |
Why?
|
| Hospitalization | 2 | 2008 | 1733 | 0.120 |
Why?
|
| Rubella | 1 | 2014 | 21 | 0.120 |
Why?
|
| Lymphopenia | 1 | 2014 | 36 | 0.120 |
Why?
|
| Consciousness Disorders | 1 | 2004 | 23 | 0.120 |
Why?
|
| Tumor Virus Infections | 1 | 2005 | 134 | 0.120 |
Why?
|
| Polyomavirus Infections | 1 | 2005 | 90 | 0.120 |
Why?
|
| Mutism | 1 | 2004 | 29 | 0.120 |
Why?
|
| Simian virus 40 | 1 | 2005 | 197 | 0.120 |
Why?
|
| Gestational Age | 2 | 2019 | 1136 | 0.110 |
Why?
|
| Viral Matrix Proteins | 2 | 2011 | 109 | 0.110 |
Why?
|
| Otitis Media, Suppurative | 1 | 2003 | 4 | 0.110 |
Why?
|
| Consensus | 1 | 2017 | 610 | 0.110 |
Why?
|
| Age Factors | 2 | 2021 | 2799 | 0.110 |
Why?
|
| Central Nervous System Viral Diseases | 1 | 2003 | 12 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1305 | 0.110 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 36 | 0.110 |
Why?
|
| Mastoiditis | 1 | 2003 | 31 | 0.110 |
Why?
|
| Syndrome | 2 | 2022 | 1115 | 0.110 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2003 | 48 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 3 | 2018 | 2396 | 0.110 |
Why?
|
| Gardnerella vaginalis | 1 | 2002 | 6 | 0.100 |
Why?
|
| Cells, Cultured | 3 | 2011 | 3046 | 0.100 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2003 | 62 | 0.100 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 2837 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 3 | 2010 | 1760 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 3526 | 0.100 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 2 | 2017 | 22 | 0.100 |
Why?
|
| United States | 7 | 2024 | 10627 | 0.100 |
Why?
|
| Risk Factors | 5 | 2019 | 10011 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2017 | 3251 | 0.100 |
Why?
|
| Feces | 1 | 2005 | 708 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 2112 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 473 | 0.100 |
Why?
|
| Sequence Alignment | 2 | 2008 | 623 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 477 | 0.090 |
Why?
|
| Infant, Premature | 3 | 2020 | 798 | 0.090 |
Why?
|
| Enterocolitis | 1 | 2011 | 24 | 0.090 |
Why?
|
| Disease Management | 1 | 2015 | 515 | 0.090 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2011 | 58 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 815 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 769 | 0.090 |
Why?
|
| Fatigue | 1 | 2022 | 217 | 0.090 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 58 | 0.090 |
Why?
|
| Nervous System | 1 | 2021 | 128 | 0.090 |
Why?
|
| Radiography | 2 | 2022 | 818 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1259 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2021 | 16000 | 0.090 |
Why?
|
| Rhizopus | 1 | 2020 | 10 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 3380 | 0.090 |
Why?
|
| Serologic Tests | 1 | 2020 | 119 | 0.090 |
Why?
|
| Infant, Premature, Diseases | 1 | 2002 | 238 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2019 | 4705 | 0.090 |
Why?
|
| Leukemia, B-Cell | 1 | 2010 | 26 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1416 | 0.090 |
Why?
|
| Bartonella henselae | 1 | 2020 | 20 | 0.090 |
Why?
|
| Cytomegalovirus Vaccines | 1 | 2009 | 6 | 0.090 |
Why?
|
| Auditory Threshold | 1 | 2019 | 17 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 287 | 0.080 |
Why?
|
| Single-Chain Antibodies | 1 | 2010 | 41 | 0.080 |
Why?
|
| Receptors, Virus | 1 | 2010 | 104 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 1873 | 0.080 |
Why?
|
| Phylogeny | 2 | 2009 | 685 | 0.080 |
Why?
|
| Health Services | 1 | 2009 | 71 | 0.080 |
Why?
|
| Vaccination | 1 | 2014 | 950 | 0.080 |
Why?
|
| Seizures | 1 | 2004 | 871 | 0.080 |
Why?
|
| Awareness | 1 | 2009 | 81 | 0.080 |
Why?
|
| Phosphoproteins | 1 | 2011 | 399 | 0.080 |
Why?
|
| Immunocompromised Host | 2 | 2010 | 300 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 677 | 0.080 |
Why?
|
| Fetal Blood | 1 | 2010 | 177 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2010 | 193 | 0.080 |
Why?
|
| Adoptive Transfer | 1 | 2010 | 237 | 0.080 |
Why?
|
| Symptom Assessment | 1 | 2019 | 98 | 0.080 |
Why?
|
| Child Day Care Centers | 1 | 2008 | 25 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 1584 | 0.070 |
Why?
|
| Doxycycline | 1 | 2018 | 117 | 0.070 |
Why?
|
| Georgia | 1 | 2017 | 29 | 0.070 |
Why?
|
| Mutation | 4 | 2014 | 5773 | 0.070 |
Why?
|
| Adenovirus Infections, Human | 1 | 2007 | 49 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 354 | 0.070 |
Why?
|
| Virus Internalization | 1 | 2017 | 54 | 0.070 |
Why?
|
| Strabismus | 1 | 2017 | 47 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 798 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2024 | 671 | 0.070 |
Why?
|
| Virion | 1 | 2017 | 149 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1149 | 0.070 |
Why?
|
| Deafness | 1 | 2017 | 81 | 0.070 |
Why?
|
| Pericardiocentesis | 1 | 2006 | 16 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2014 | 1012 | 0.070 |
Why?
|
| Birth Weight | 1 | 2017 | 336 | 0.060 |
Why?
|
| Pericardial Effusion | 1 | 2006 | 63 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2024 | 1588 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2008 | 2698 | 0.060 |
Why?
|
| Genotype | 2 | 2008 | 2540 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1683 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2019 | 3329 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2009 | 1480 | 0.060 |
Why?
|
| False Negative Reactions | 2 | 2005 | 90 | 0.060 |
Why?
|
| Comorbidity | 1 | 2019 | 1497 | 0.060 |
Why?
|
| Immunization | 1 | 2006 | 308 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 2848 | 0.060 |
Why?
|
| Mothers | 2 | 2017 | 350 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2307 | 0.060 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2019 | 906 | 0.050 |
Why?
|
| Respiratory Tract Infections | 1 | 2006 | 263 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2017 | 1167 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2002 | 22 | 0.050 |
Why?
|
| Organophosphonates | 1 | 2002 | 19 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2017 | 878 | 0.050 |
Why?
|
| Cytosine | 1 | 2002 | 56 | 0.050 |
Why?
|
| Ascomycota | 1 | 2022 | 25 | 0.050 |
Why?
|
| Genes, Viral | 2 | 2009 | 183 | 0.050 |
Why?
|
| Viral Load | 1 | 2024 | 382 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2002 | 80 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2013 | 400 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2002 | 141 | 0.050 |
Why?
|
| Quality of Life | 1 | 2021 | 1932 | 0.050 |
Why?
|
| Self Report | 1 | 2014 | 514 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2010 | 12 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 12116 | 0.050 |
Why?
|
| Echocardiography | 1 | 2006 | 1059 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2013 | 696 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 353 | 0.040 |
Why?
|
| Education, Medical | 1 | 2014 | 285 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2010 | 44 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2013 | 867 | 0.040 |
Why?
|
| Latin America | 1 | 2010 | 89 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 4221 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2021 | 209 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2009 | 42 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 252 | 0.040 |
Why?
|
| Disaster Planning | 1 | 2009 | 65 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2010 | 118 | 0.040 |
Why?
|
| Mass Screening | 1 | 2005 | 790 | 0.040 |
Why?
|
| Point Mutation | 1 | 2010 | 348 | 0.040 |
Why?
|
| Maternal Welfare | 1 | 2008 | 14 | 0.040 |
Why?
|
| Leukocytosis | 1 | 2008 | 42 | 0.040 |
Why?
|
| Serotyping | 1 | 2008 | 178 | 0.040 |
Why?
|
| Infection Control | 1 | 2009 | 160 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2008 | 237 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2008 | 105 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2009 | 773 | 0.040 |
Why?
|
| Probability | 1 | 2008 | 322 | 0.040 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2008 | 79 | 0.040 |
Why?
|
| Immunologic Tests | 1 | 2007 | 23 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2022 | 738 | 0.030 |
Why?
|
| Milk, Human | 1 | 2019 | 300 | 0.030 |
Why?
|
| Digitoxin | 1 | 1975 | 7 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 501 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2005 | 145 | 0.030 |
Why?
|
| Animals | 7 | 2022 | 33718 | 0.030 |
Why?
|
| Audiometry | 1 | 2005 | 21 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 1975 | 113 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2009 | 547 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2008 | 280 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 86 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 1975 | 140 | 0.030 |
Why?
|
| Nasal Lavage Fluid | 1 | 2004 | 14 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 542 | 0.030 |
Why?
|
| Erythrocytes | 1 | 1975 | 206 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2006 | 481 | 0.030 |
Why?
|
| ROC Curve | 1 | 2006 | 557 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 2017 | 246 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 262 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2002 | 1013 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 3659 | 0.030 |
Why?
|
| Calcinosis | 2 | 2003 | 168 | 0.030 |
Why?
|
| Laboratories | 1 | 2004 | 83 | 0.030 |
Why?
|
| Hepatomegaly | 1 | 2003 | 21 | 0.030 |
Why?
|
| Scalp Dermatoses | 1 | 2003 | 5 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2010 | 995 | 0.030 |
Why?
|
| Peptides | 1 | 1997 | 796 | 0.030 |
Why?
|
| Hyperbilirubinemia | 1 | 2003 | 41 | 0.030 |
Why?
|
| Splenomegaly | 1 | 2003 | 34 | 0.030 |
Why?
|
| Asia | 1 | 2003 | 107 | 0.030 |
Why?
|
| World Health Organization | 1 | 2003 | 111 | 0.030 |
Why?
|
| Nasal Mucosa | 1 | 2003 | 65 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2010 | 966 | 0.030 |
Why?
|
| Seasons | 1 | 2004 | 303 | 0.030 |
Why?
|
| Algorithms | 1 | 2009 | 1595 | 0.030 |
Why?
|
| Canada | 1 | 2003 | 294 | 0.030 |
Why?
|
| Incidence | 1 | 2010 | 3050 | 0.030 |
Why?
|
| Abscess | 1 | 2003 | 138 | 0.020 |
Why?
|
| Metronidazole | 1 | 2002 | 155 | 0.020 |
Why?
|
| Cell Line | 1 | 2007 | 2774 | 0.020 |
Why?
|
| Creatinine | 1 | 2003 | 380 | 0.020 |
Why?
|
| Middle Aged | 4 | 2017 | 25964 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 513 | 0.020 |
Why?
|
| Logistic Models | 1 | 2006 | 1796 | 0.020 |
Why?
|
| Base Sequence | 1 | 2005 | 3092 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 4494 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2010 | 13 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 1293 | 0.020 |
Why?
|
| Blood Cells | 1 | 2010 | 49 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2010 | 57 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2010 | 170 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1041 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 939 | 0.020 |
Why?
|
| Swine Diseases | 1 | 2009 | 36 | 0.020 |
Why?
|
| Reassortant Viruses | 1 | 2009 | 34 | 0.020 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2009 | 113 | 0.020 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2009 | 57 | 0.020 |
Why?
|
| Antigens, CD19 | 1 | 2010 | 178 | 0.020 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2009 | 59 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2006 | 1073 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2009 | 171 | 0.020 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2009 | 193 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 294 | 0.020 |
Why?
|
| Microbiological Techniques | 1 | 2007 | 33 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 510 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 752 | 0.020 |
Why?
|
| Phosphogluconate Dehydrogenase | 1 | 1976 | 1 | 0.020 |
Why?
|
| Neurospora | 1 | 1976 | 2 | 0.020 |
Why?
|
| Neurospora crassa | 1 | 1976 | 5 | 0.020 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1976 | 15 | 0.020 |
Why?
|
| Aortic Arch Syndromes | 1 | 1975 | 11 | 0.020 |
Why?
|
| Takayasu Arteritis | 1 | 1975 | 13 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1422 | 0.020 |
Why?
|
| Carbonic Anhydrases | 1 | 1975 | 25 | 0.020 |
Why?
|
| Cadmium | 1 | 1975 | 29 | 0.020 |
Why?
|
| Swine | 1 | 2009 | 1154 | 0.020 |
Why?
|
| Mercury | 1 | 1975 | 27 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 672 | 0.020 |
Why?
|
| Phenobarbital | 1 | 1975 | 36 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 1975 | 153 | 0.020 |
Why?
|
| Zinc | 1 | 1975 | 128 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 1975 | 424 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 17486 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 3277 | 0.010 |
Why?
|
| Blood | 1 | 2002 | 105 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2002 | 151 | 0.010 |
Why?
|
| NADP | 2 | 1976 | 47 | 0.010 |
Why?
|
| Cattle | 2 | 1975 | 559 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1975 | 1019 | 0.010 |
Why?
|
| Kinetics | 2 | 1976 | 1313 | 0.010 |
Why?
|
| Binding Sites | 2 | 1975 | 1292 | 0.010 |
Why?
|
| Liver | 1 | 1975 | 1734 | 0.010 |
Why?
|
| Protein Binding | 2 | 1975 | 1742 | 0.010 |
Why?
|
| Electrophoresis, Capillary | 1 | 1997 | 12 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1975 | 58 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1975 | 44 | 0.010 |
Why?
|
| Digitoxigenin | 1 | 1975 | 6 | 0.010 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 41 | 0.010 |
Why?
|
| Hydroxylation | 1 | 1975 | 45 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 1997 | 326 | 0.010 |
Why?
|
| Rats | 2 | 1975 | 3631 | 0.010 |
Why?
|
| Enzyme Repression | 1 | 1976 | 3 | 0.000 |
Why?
|
| Linolenic Acids | 1 | 1976 | 2 | 0.000 |
Why?
|
| Pentosephosphates | 1 | 1976 | 8 | 0.000 |
Why?
|
| Theophylline | 1 | 1976 | 29 | 0.000 |
Why?
|
| Arteritis | 1 | 1975 | 6 | 0.000 |
Why?
|
| Drug Stability | 1 | 1976 | 55 | 0.000 |
Why?
|
| Styrenes | 1 | 1975 | 6 | 0.000 |
Why?
|
| NAD | 1 | 1976 | 48 | 0.000 |
Why?
|
| Stimulation, Chemical | 1 | 1975 | 64 | 0.000 |
Why?
|
| Lymphatic Diseases | 1 | 1975 | 31 | 0.000 |
Why?
|
| Epoxy Compounds | 1 | 1975 | 18 | 0.000 |
Why?
|
| Methylcholanthrene | 1 | 1975 | 19 | 0.000 |
Why?
|
| Ribs | 1 | 1975 | 44 | 0.000 |
Why?
|
| Culture Media | 1 | 1976 | 182 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1975 | 288 | 0.000 |
Why?
|
| Genetic Linkage | 1 | 1976 | 454 | 0.000 |
Why?
|
| Glutathione | 1 | 1975 | 193 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1975 | 836 | 0.000 |
Why?
|
| Heterozygote | 1 | 1976 | 672 | 0.000 |
Why?
|
| Aorta | 1 | 1975 | 541 | 0.000 |
Why?
|
| Hypertension, Pulmonary | 1 | 1975 | 431 | 0.000 |
Why?
|